两种方案治疗社区获得性肺炎的疗效和药物经济学比较研究

Efficacy and Pharmaceutical- economic Analysis of Two Treatments of Community Acquired Pneumonia

目的探讨哌拉西林钠/舒巴坦钠合用阿奇霉素(A组)和美洛西林钠/舒巴坦钠合用左氧氟沙星(B组)两种用药方案治疗社区获得性肺炎(CAP)的疗效与费用。方法采用回顾性调查方法,收集九江市第一人民医院和九江学院附属医院2010年10月—2012年8月住院的CAP患者的病例资料,从中筛选出采用A组、B组治疗方案的病例,对2种方案的治疗效果、用药费用、成本-效果比(C/E)进行比较分析。结果两组治疗CAP的临床疗效间差异无统计学意义(P>0.05)。两组体温、痰色质、咳嗽、肺部啰音、X线胸片等敏感指标的恢复情况间差异均无统计学意义(P>0.05)。成本-效果分析表明,B组每单位疗效的用药费用,即C/E(19.44,1 314.3/67.6)低于A组(37.04,2 529.7/68.3)。结论美洛西林钠/舒巴坦钠合用左氧氟沙星治疗CAP的疗效与哌拉西林钠/舒巴坦钠合用阿奇霉素相当,但治疗费用低于后者。

Objective To compare the curative efficacy and cost between piperacillin sodium / sulbactam combined with azithromycin and mezlocillin sodium / sulbactam combined with levofloxacin in the treatment of community acquired pneumonia( CAP). Methods Retrospective survey methodology was used to collect the clinical data of inpatients with CAP in First People's Hospital of Jiujiang and Jiujiang University Hospital from October 2010 to August 2012. The patients were divided into two groups based on their treatment,namely group A with piperacillin sodium / sulbactam combined with azithromycin and group B with mezlocillin sodium / sulbactam combined with levofloxacin. The curative efficacy,drug costs,and cost- effectiveness ratios were compared between group A and group B. Results No significant difference was noted on effective rate between group A and group B( P > 0. 05). There were no significant differences on body temperature,sputum color and quality,cough,pulmonary rales,chest X ray results after the treatment between group A and group B( P > 0. 05). Cost- effectiveness analysis showed that drug cost per unit of curative effect in group B( 19. 44,1 314. 3 /67. 6) was lower than that in group A( 37. 04,2 529. 7 /68. 3). Conclusion Curative efficacy of mezlocillin sodium / sulbactam combined with levofloxacin is almost the same with that of piperacillin sodium / sulbactam combined with azithromycin,but the former's cost is lower.